The Cigna Group
278.17USD
+2.3400 (+0.85%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $7.49▼ | $7.62 | 5 | 16 |
| Next quarter | $7.42▼ | $7.43 | 15 | 6 |
| Current year | $30.51▲ | $30.4 | 19 | 2 |
| Next year | $33.49▼ | $33.49 | 17 | 3 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $7.6 | $7.78 | +0.18 (+2.4%) |
| 2026-03-31 | $7.61 | $7.79 | +0.18 (+2.4%) |
| 2025-12-31 | $7.88 | $8.08 | +0.20 (+2.5%) |
| 2025-09-30 | $7.64 | $7.83 | +0.19 (+2.5%) |
353 ratings from 37 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Jefferies | Downgraded from Buy | Hold | $336 $307 | Aug 4, 2026 |
| Raymond James | Downgraded from Strong Buy | Outperform | $350 $320 | Aug 3, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $305 $307 | Jul 31, 2026 |
| Guggenheim | Maintained | Buy | $338 $361 | Jul 31, 2026 |
| Barclays | Maintained | Equal-Weight | $304 $310 | Jul 31, 2026 |
| Bernstein | Maintained | Outperform | $371 $381 | Jul 9, 2026 |
| Mizuho | Maintained | Outperform | $330 $340 | Jun 8, 2026 |
| Barclays | Downgraded from Overweight | Equal-Weight | $310 $304 | May 26, 2026 |
| UBS | Maintained | Buy | $375 $400 | May 22, 2026 |
| Morgan Stanley | Maintained | Overweight | $355 $361 | May 20, 2026 |
| Deutsche Bank | Downgraded from Buy | Hold | $303 $302 | May 20, 2026 |
| Bernstein | Maintained | Outperform | $358 $371 | May 5, 2026 |
| Guggenheim | Maintained | Buy | $334 $338 | May 4, 2026 |
| RBC Capital | Maintained | Outperform | $333 $337 | May 1, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $325 $340 | May 1, 2026 |
| Barclays | Maintained | Overweight | $303 $310 | May 1, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $300 $305 | May 1, 2026 |
| Jefferies | Maintained | Buy | $333 $330 | Apr 20, 2026 |
| Bernstein | Upgraded from Market Perform | Outperform | $307 $358 | Mar 12, 2026 |
| Piper Sandler | Reiterated | Overweight | $374 $370 | Mar 3, 2026 |
| Truist Securities | Reiterated | Buy | $320 $350 | Feb 17, 2026 |
| TD Cowen | Maintained | Buy | $333 $338 | Feb 9, 2026 |
| RBC Capital | Maintained | Outperform | $344 $333 | Feb 6, 2026 |
| Barclays | Maintained | Overweight | $305 $303 | Feb 6, 2026 |
| Guggenheim | Maintained | Buy | $318 $334 | Feb 6, 2026 |
59 filings from 24 insiders · 14 buy / 4 sell over 6m
Officers and directors of CI, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Neville EverettOfficer, See Remarks | Sell | 617 | $284.05 | $175k | Sep 3, 2026 |
| Evanko Brian COfficer, See Remarks | GrantEmployee Stock Option (Right to Buy) | 6.7k | — | — | Sep 1, 2026 |
| Evanko Brian COfficer, See Remarks | Grant | 3.1k | — | — | Sep 1, 2026 |
| Kurian GeorgeDirector | GrantPhantom Stock Units | 108.664 | $276.08 | $30k | Aug 31, 2026 |
| JONES NICOLE S.Officer | Sell | 2.7k | $279.61 | $749k | Aug 18, 2026 |
| JONES NICOLE S.Officer | Exercise | 15.3k | $192.02 | $2.95M | Aug 5, 2026 |
| JONES NICOLE S.Officer | Sell | 19.4k | $276.27 | $5.37M | Aug 4, 2026 |
| KATES JAMIE GOfficer | Exercise | 899 | $152.89 | $137k | Jun 12, 2026 |
| KATES JAMIE GOfficer | Sell | 899 | $298.61 | $268k | Jun 12, 2026 |
| CORDANI DAVID MChief Executive Officer | Exercise | 212.5k | $149.14 | $36.21M | May 13, 2026 |
| CORDANI DAVID MChief Executive Officer | Sell | 201.9k | $286.83 | $59.11M | May 12, 2026 |
| KURIAN GEORGEDirector | Grant | 782 | — | — | Apr 22, 2026 |
| MCCLELLAN MARK BDirector | Grant | 782 | — | — | Apr 22, 2026 |
| ROSS KIMBERLY ADirector | Grant | 782 | — | — | Apr 22, 2026 |
| OZUAH PHILLIPDirector | Grant | 782 | — | — | Apr 22, 2026 |
| HATHI NEESHADirector | Grant | 782 | — | — | Apr 22, 2026 |
| HENNIGAN MICHAEL JDirector | Grant | 782 | — | — | Apr 22, 2026 |
| WISEMAN ERIC CDirector | Grant | 782 | — | — | Apr 22, 2026 |
| MAZZARELLA KATHLEEN M.Director | Grant | 782 | — | — | Apr 22, 2026 |
| FOSS ERIC J.Director | Grant | 782 | — | — | Apr 22, 2026 |
No analyst notes on CI yet.
Analyst Ratings
24 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 6 | 13 | 5 | 0 | 0 | Buy1.96 |
| 1 mo ago | 5 | 15 | 4 | 0 | 0 | Buy1.96 |
| 2 mo ago | 5 | 15 | 4 | 0 | 0 | Buy1.96 |